GSK’s newest neu­ro pact is with ABL Bio, a Sanofi-part­nered South Ko­re­an biotech

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

ABL Bio …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER